Subcutaneous ADAMTS13 Formulation Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of ADAMTS13, a large and labile protein, face challenges in subcutaneous administration due to low bioavailability and stability issues, limiting their use in treating ADAMTS13 and VWF-related disorders.
Innovation Solution
A method for subcutaneously administering ADAMTS13 with a therapeutically effective amount of 20-4000 activity units per kilogram, achieving up to 80% bioavailability compared to intravenous administration, using stabilized formulations that include a sub-physiological to physiological concentration of pharmaceutically acceptable salts, sugars, and non-ionic surfactants to enhance stability and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If ADAMTS13 is administered subcutaneously, then patient compliance and convenience are improved, but bioavailability is reduced
Solution Approach 1:
The patent introduces specific formulation components as intermediaries to facilitate ADAMTS13 absorption. These include albumin (as a carrier protein), polysaccharides (such as dextran or hyaluronic acid), and amino acid sequences that act as penetration enhancers. These intermediaries mediate between the ADAMTS13 protein and the subcutaneous tissue, enabling effective absorption while maintaining protein stability and activity.
Solution Approach 2:
The patent modifies critical parameters of the ADAMTS13 formulation including molecular weight (through proteolytic cleavage to generate fragments between 1-50 kDa), charge distribution, hydrophobicity, and glycosylation patterns. These parameter changes optimize the protein's pharmacokinetic properties for subcutaneous absorption, transforming it from a poorly absorbed large protein into a formulation with enhanced bioavailability suitable for subcutaneous administration.
2Ease of operation
If ADAMTS13 is administered subcutaneously, then treatment convenience is improved, but protein stability is reduced
Solution Approach 1:
The patent segments the ADAMTS13 protein into smaller functional fragments through controlled proteolytic cleavage. By generating peptide fragments between 1-50 kDa (preferably 10-30 kDa), the protein is divided into more stable, absorbable units that maintain biological activity while improving formulation stability and reducing aggregation tendencies in subcutaneous formulations.
Solution Approach 2:
The patent creates composite formulations combining ADAMTS13 fragments with stabilizing excipients including albumin (0.1-10% w/v), polysaccharides (dextran, hyaluronic acid, chitosan), amino acids, and buffer systems. These composite materials work synergistically to protect the protein from degradation, maintain proper conformation, and ensure stability during storage and administration.
Data Source
AI summary
This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.